You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Immunotherapy, A2aR, PDR001, NIR178, NSCLC, solid tumors

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Solid Tumor, ARID1A Gene Mutation Trial in Greenville (Tazemetostat)

Suspended
  • Solid Tumor
  • ARID1A Gene Mutation
  • Greenville, South Carolina
    Prisma Health Cancer Institute
Jan 10, 2023

Carcinoma, Renal Cell Trial in Worldwide (DFF332, RAD001, PDR001)

Recruiting
  • Carcinoma, Renal Cell
  • Duarte, California
  • +10 more
Jun 13, 2022

NSCLC, Tumor Metastasis Trial in Worldwide (LY3537982, Pembrolizumab, Placebo)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Neoplasm Metastasis
  • Tucson, Arizona
  • +217 more
Nov 1, 2023

Tumor, Solid Trial in Morristown, Houston (BDB001)

Active, not recruiting
  • Tumor, Solid
  • Morristown, New Jersey
  • +1 more
Nov 9, 2021

Locally Advanced Solid Tumor, Metastatic Solid Tumor Trial in United States (NVL-655)

Recruiting
  • Locally Advanced Solid Tumor
  • Metastatic Solid Tumor
  • Orange, California
  • +13 more
Jan 31, 2023

Solid Tumor, Adult, NSCLC, Advanced Cancer Trial (Adagrasib, nab-Sirolimus)

Not yet recruiting
  • Solid Tumor, Adult
  • +4 more
  • (no location specified)
Apr 24, 2023

Advanced Solid Tumor, Metastatic Solid Tumor, Lung Cancer Trial in Seoul, Incheon (WM-A1-3389, Pembrolizumab)

Not yet recruiting
  • Advanced Solid Tumor
  • +7 more
  • WM-A1-3389
  • Pembrolizumab
  • Seoul, Seocho-gu, Korea, Republic of
  • +1 more
May 14, 2023

ALK-positive Advanced NSCLC Trial in Worldwide (Brigatinib)

Active, not recruiting
Has Results
  • ALK-positive Advanced NSCLC
  • Orange, California
  • +79 more
Nov 15, 2022

NSCLC, IMMUNOTHERAPY, QUANTIFICATION OF CELL-FREE DNA Trial in France (Molecular monitoring by quantification of cell-free DNA)

Recruiting
  • NSCLC
  • +2 more
  • Molecular monitoring by quantification of cell-free DNA
  • Besançon, France
  • +7 more
Nov 18, 2022

Cancer Trial in Barcelona (PBF-999)

Completed
  • Cancer
  • Barcelona, Spain
    Vall d'Hebron institute of oncology (VHIO)
Jan 24, 2023

Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma Trial in Irvine, Chicago, Boston

Not yet recruiting
  • Advanced Solid Tumor
  • +4 more
  • Irvine, California
  • +2 more
Nov 27, 2023

Ovarian Cancer Trial in Pittsburgh (Pembrolizumab, ALX148, Doxorubicin)

Not yet recruiting
  • Ovarian Cancer
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Jul 19, 2022

NSCLC, Urothelial Cancer Trial in Worldwide (Avelumab 800 mg in combination with pemetrexed / carboplatin, Avelumab 800 mg in

Active, not recruiting
Has Results
  • Non-small Cell Lung Cancer
  • Urothelial Cancer
  • Avelumab 800 mg in combination with pemetrexed / carboplatin
  • +3 more
  • Tucson, Arizona
  • +45 more
Oct 13, 2022

NSCLC, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1) Trial (MK-2870, Pembrolizumab, Carboplatin)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • +4 more
  • MK-2870
  • +2 more
  • (no location specified)
Sep 15, 2023

Immune-related Adverse Event, Dietary Habits Trial (Food box containing 30 different plants)

Not yet recruiting
  • Immune-related Adverse Event
  • Dietary Habits
  • Food box containing 30 different plants
  • (no location specified)
Apr 14, 2023

Ovarian Cancer, Bladder Cancer, Non Small Cell Lung Cancer Trial in Worldwide (INCB106385, INCMGA00012)

Recruiting
  • Ovarian Cancer
  • +10 more
  • West Hollywood, California
  • +27 more
Jun 27, 2022

Tumors by Site Trial in Worldwide (Relatlimab, Nivolumab, BMS-986213)

Active, not recruiting
  • Neoplasms by Site
  • Relatlimab
  • +2 more
  • La Jolla, California
  • +52 more
Feb 10, 2022

Metastatic Cancer Trial in Nanchang (High- and Low-dose radiotherapy)

Recruiting
  • Metastatic Cancer
  • High- and Low-dose radiotherapy
  • Nanchang, Jiangxi, China
  • +1 more
Mar 6, 2023

Carcinoma, Non-squamous Non-small-cell Lung Trial in Worldwide (Pembrolizumab, Pemetrexed, Carboplatin)

Active, not recruiting
  • Carcinoma, Non-squamous Non-small-cell Lung
  • Pembrolizumab
  • +4 more
  • Birmingham, Alabama
  • +177 more
Aug 22, 2022

NSCLC, NSCLC Trial in Bronx (PembroRT, ChemoRT)

Active, not recruiting
  • Non-small Cell Lung Cancer, NSCLC
  • Bronx, New York
    Montefiore Medical Center
Dec 6, 2022

Advanced NSCLC Trial (Trilaciclib+Envafolimab+Docetaxel, Envafolimab+Docetaxel, Docetaxel)

Not yet recruiting
  • Advanced Non-Small Cell Lung Cancer
  • (no location specified)
Jun 16, 2023

Locally Advanced Solid Tumor, Metastatic Solid Tumor Trial in Worldwide (NVL-520)

Recruiting
  • Locally Advanced Solid Tumor
  • Metastatic Solid Tumor
  • Orange, California
  • +18 more
Oct 6, 2022

Patients With Advanced Solid Tumor (Excluding NSCLC, SCLC, and Mesothelioma) With Results From a Multi-gene Next-generation

Not yet recruiting
  • Patients With Advanced Solid Tumor (Excluding NSCLC, SCLC, and Mesothelioma) With Results From a Multi-gene Next-generation Sequencing (NGS) Panel (>30 Genes)
  • Minimal documentation
  • Extended documentation
  • Mannheim, Baden-Württemberg, Germany
  • +1 more
Jan 18, 2023

Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, NSCLC Trial in United States (LYL797)

Recruiting
  • Triple Negative Breast Cancer
  • +14 more
  • LYL797
  • Scottsdale, Arizona
  • +10 more
Jan 30, 2023

Advanced Solid Tumor, NSCLC Trial in Shanghai (XZB-0004)

Not yet recruiting
  • Advanced Solid Tumor
  • NSCLC
  • Shanghai, Shanghai, China
    Shanghai Pulmonary Hospital
Mar 5, 2023